Edivoxetine for ADHD
Edivoxetine (LY2216684) is a selective noradrenaline reuptake inhibitor.
An 8-week double-blind, fixed-dose study in n = 340 children aged 6 to 17 years showed a statistically significant improvement in the mean ADHD-RS total score at 0.2 mg/kg/day (Effect size: 0.51) and 0.3 mg/kg/day (Effect size: 0.54) compared to placebo. OROS-MPH reached 0.69.1
Edivoxetine 0.3 mg/kg/day also improved the Conners CBRS score for oppositional defiant behavior and generalized anxiety symptoms.2
Side effects were found to be:1
- Nausea
- reduced appetite
- Sedation, drowsiness
- Irritability
- Increase in systolic and diastolic blood pressure
- Increase in heart rate
Lin DY, Kratochvil CJ, Xu W, Jin L, D’Souza DN, Kielbasa W, Allen AJ (2014): A randomized trial of edivoxetine in pediatric patients with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2014 May;24(4):190-200. doi: 10.1089/cap.2013.0043. PMID: 24840045; PMCID: PMC4026219. RCT ↥ ↥
Ilipilla G, Arnold LE (2024): The role of adrenergic neurotransmitter reuptake inhibitors in the ADHD armamentarium. Expert Opin Pharmacother. 2024 Jun;25(8):945-956. doi: 10.1080/14656566.2024.2369197. PMID: 38900676. REVIEW ↥